PFIZER INC Equity Method Investment, Other than Temporary Impairment
PFIZER INC (PFE) reported Equity Method Investment, Other than Temporary Impairment of $241.00 million for the 3-month period ending 2016-12-31, per its 10-K filed 2019-02-28.
Discontinued › Income Statement › Other Income
us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment · last filed 2019-02-28
- PFIZER INC equity method investment, other than temporary impairment for the quarter ending 2016-12-31 was $241.00M.
- PFIZER INC equity method investment, other than temporary impairment for the quarter ending 2016-07-03 was $130.00M.
- PFIZER INC equity method investment, other than temporary impairment for the quarter ending 2016-04-03 was $81.00M.
- PFIZER INC equity method investment, other than temporary impairment for fiscal 2016 was $452.00M.
- PFIZER INC equity method investment, other than temporary impairment for fiscal 2012 was $55.00M.
| Period end | Equity Method Investment, Other than Temporary Impairment 3 month | Equity Method Investment, Other than Temporary Impairment 6 month | Equity Method Investment, Other than Temporary Impairment 12 month |
|---|---|---|---|
| 2016-12-31 | $241.00M 10-K · filed 2019-02-28 | $452.00M 10-K · filed 2019-02-28 | |
| 2016-07-03 | $130.00M 10-K · filed 2019-02-28 | $211.00M derived: sum of 2 quarters · filed 2019-02-28 | |
| 2016-04-03 | $81.00M 10-K · filed 2019-02-28 | ||
| 2012-12-31 | $55.00M 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |